SCHEMBL21773000

SCHEMBL21773000

COc1ccc(CN(c2cccc(F)n2)S(=O)(=O)c2cnc(F)c(Cl)c2)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 4/20 0.42
CNR2 P34972 3/20 0.40
MMP1 P03956 1/20 0.40
MMP9 P14780 1/20 0.40
ACLY P53396 1/20 0.39
TAS2R14 Q9NYV8 2/20 0.39
PGR P06401 2/20 0.39
CNR1 P21554 2/20 0.39
NR3C1 P04150 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
PTGER1 P34995 3/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
AVPR2 P30518 1/20 0.37
OXTR P30559 1/20 0.37
AVPR1A P37288 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30845602 1.00 TRPM8 (0.42) TRPM8CNR2MMP1MMP9ACLY
SCHEMBL31018047 0.87 TP53 (0.39) TRPM8ALDH1A1LMNAMEN1KMT2A
SCHEMBL21783443 0.87 TP53 (0.39) TRPM8ALDH1A1LMNAMEN1KMT2A
SCHEMBL31566612 0.78 CNR2 (0.34) TRPM8CNR2MMP1MMP9ACLY
SCHEMBL31566999 0.78 ACLY (0.41) TRPM8CNR2MMP1MMP9ACLY
SCHEMBL31567096 0.78 TAS2R14 (0.41) CNR2ACLYTAS2R14PGRCNR1
SCHEMBL31566915 0.78 HDAC8 (0.39) TRPM8CNR2MMP1MMP9ACLY
SCHEMBL31018013 0.77 ALDH1A1 (0.40) CNR2MMP1MMP9TAS2R14PGR
SCHEMBL31566904 0.77 MMP9 (0.46) TRPM8CNR2MMP1MMP9TAS2R14
SCHEMBL21772960 0.77 SCN8A (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112638898-B Heteroaryl substituted sulfonamide compounds and their use as sodium channel inhibitors 泽农医药公司 2024-04-09 CN disclosed
CN-112638898-A Heteroaryl substituted sulfonamide compounds and their use as sodium channel inhibitors 泽农医药公司 2021-04-09 CN disclosed
US-10752623-B2 Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors XENON PHARMACEUTICALS INC. (CA) 2020-08-25 US disclosed
US-10752623-B2 Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors XENON PHARMACEUTICALS INC. (CA) 2020-08-25 US disclosed
WO-2020047312-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2020-03-05 WO disclosed
US-20200071313-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2020-03-05 US disclosed
US-20200071313-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2020-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071313-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS SCN1A, SCN2A, SCN2B TRPM8 41/4885CNR2 371/4885MMP1 4254/4885
US-10752623-B2 Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors SCN1A, SCN2A, SCN2B TRPM8 41/4885CNR2 371/4885MMP1 4254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.